◆ AfterJournal
Author guidelines · Contact
Health & Fitness 20 Nov 2026

Stopping statins in people 70 and older raised events to 12.7% from 9.2% in STREAM

STREAM, published in NEJM on Nov. 7, 2026, tested stopping statins in adults 70 and older with no known heart disease. Over a median 103 weeks, 12.7% who stopped had a heart attack or stroke or died, against 9.2% who continued, yet stopping met the 5.2-week noninferiority margin.

Stopping statins in people 70 and older raised events to 12.7% from 9.2% in STREAM

STREAM was set up to test whether adults aged 70 and older who take a statin to prevent a first heart attack or stroke, and who also live with several chronic conditions, can stop the drug and fare no worse, within a margin fixed in advance, than those who keep taking it. The New England Journal of Medicine published its results on Nov. 7, 2026.

In the trial, 12.7% of participants who stopped their statins had a heart attack or stroke or died over a median 103 weeks, against 9.2% of those who kept taking them, and the trial still met its prespecified noninferiority margin, according to HCPLive. The result bears on people past 75 who have never had a heart attack or stroke, because STREAM's participants had a mean age of 77.5 and no known cardiovascular disease. Study author Redberg said in HCPLive's coverage that the small added risk means no general recommendation can be made.

STREAM enrolled 1,880 adults aged 70 or older who had at least two chronic conditions, no known atherosclerotic cardiovascular disease (ASCVD) and at least a year on a statin for primary prevention, according to HCPLive's summary of the trial. It was an open-label trial run at 24 sites in Switzerland, the Netherlands and France.

Enrollment ran from November 2021 to April 2025, and HCPLive gives the participants' mean age as 77.5, with 32.1% having diabetes. Primary prevention means taking a statin to prevent a first heart attack or stroke, so people taking the drug after one of those events, known as secondary prevention, were not eligible.

The noninferiority design and the focus on older adults with several conditions were set out in the published STREAM study protocol, which describes a randomised trial in multimorbid older adults without cardiovascular disease.

The main measure was restricted mean event-free survival, the average number of weeks participants went without a heart attack, stroke or death during the trial window. In HCPLive's account of the results, it was 96.5 weeks in the group that stopped and 98.5 weeks in the group that continued, a gap of 2.0 weeks (95% CI, 0.3 to 3.7 weeks shorter with stopping).

The investigators had set a margin of 5.2 weeks in advance. Noninferiority means the observed gap stayed inside that margin, so stopping was judged no worse than continuing by more than the agreed amount. The confidence interval for the 2.0-week gap does not include zero.

HCPLive's event counts show that over a median 103 weeks, the composite outcome occurred in 119 of 938 STREAM participants who stopped (12.7%) and 87 of 942 who continued (9.2%), a hazard ratio of 1.38. Rodondi, the paper's first author, put the gap at about one extra event for every 40 people over two years, in remarks quoted by Healio.

In a subset of 235 STREAM participants measured at 12 months, LDL cholesterol averaged 176.0 mg/dL in the stop group and 99.4 mg/dL in the continue group, HCPLive's figures show. Serious adverse events in the first two years were reported in 43.0% of those who stopped and 39.8% of those who continued, so stopping did not bring fewer serious adverse events.

A doctor and an older patient looking over a printed cholesterol lab report at a clinic desk
A doctor and an older patient looking over a printed cholesterol lab report at a clinic desk - Photo: Pexels

Healio also published STREAM figures from follow-up that ran up to four years, and its account of the longer follow-up describes increased cardiovascular risk "among a small number of older adults in the discontinuation group." In that window the gaps for heart attack and stroke were slightly wider than in the two-year figures, as the list below shows.

  • STREAM composite of heart attack, stroke or death over a median 103 weeks: 12.7% of those who stopped, 9.2% of those who continued (HCPLive).
  • STREAM heart attack: nonfatal heart attack in 1.4% of those who stopped and 0.6% of those who continued in the first two years (HCPLive); heart attack in 1.6% and 0.6% with follow-up up to four years (Healio).
  • STREAM ischemic stroke: 1.9% of those who stopped and 0.8% of those who continued in the first two years (HCPLive); 2.2% and 0.8% with follow-up up to four years (Healio).
  • STREAM deaths: 8.2% of those who stopped and 6.9% of those who continued in the first two years (HCPLive); 9.8% and 8% with follow-up up to four years (Healio).

The STREAM data and safety monitoring board recommended that participants who had stopped their statins discuss restarting them with their care team, according to the American College of Cardiology's write-up of the results. The ACC describes the result as noninferior at two years and notes that Rodondi stressed shared decision-making between patients and their doctors.

A pharmacist handing a paper prescription bag across a counter to an older customer
A pharmacist handing a paper prescription bag across a counter to an older customer - Photo: Pexels

A separate French study, the SAGA/SITE trial, enrolled 1,160 patients aged 75 and older with no ASCVD. Over three years, 7.2% (35 of 484) of those who stopped statins died, against 7.9% (48 of 604) of those who continued, according to STAT's August report on the trial.

STAT quoted Bhattacharya as saying the French result "will not change anything" for most US patients over 75, and Lloyd-Jones as saying the choice "should be an individualized decision."

SAGA/SITE ran in 291 French primary care offices and was published in Lancet Healthy Longevity. Its between-group difference in mortality was -0.68% (95% CI, -3.95% to 2.60%) against a 5% noninferiority margin, and a Yale editorial cited in TCTMD's coverage of the French trial says the findings do not support routine deprescribing.

The SAGA/SITE figures in the STAT and TCTMD coverage are for death over three years in patients 75 and older with no ASCVD. STREAM counted heart attacks and strokes as well as deaths, in people 70 and older who also had at least two chronic conditions, so the French mortality figures are not a second test of STREAM's composite outcome.

HCPLive's coverage of STREAM also refers to STAREE, a trial in which atorvastatin reduced major cardiovascular events in older adults without improving disability-free survival.

Amit Khera prefers to describe the STREAM result as an "acceptable risk" rather than "safe", according to the cardiologists' comments gathered in Healio's article on the trial.

Redberg, named by HCPLive as a study author, said: "This small, increased risk of cardiovascular events means that one cannot make a general recommendation." HCPLive also quotes Redberg describing stopping as generally safe for most people and calling for shared decision-making.

Who the STREAM result covers

GroupEnrolled in STREAM?What the sources saySource
Aged 75 or older, no prior cardiovascular diseasePartly. Adults 70 and older were eligible, and the mean age was 77.5No result for a 75-and-older age band is reported in the HCPLive, Healio or ACC coverageHCPLive, Healio, ACC
Prior heart attack or strokeNo. People with known ASCVD were excludedSTREAM gives no evidence on stopping statins after a heart attack or strokeHCPLive
DiabetesYes. 32.1% of the 1,880 participantsParticipants with diabetes were among the 1,880 whose overall results are reported aboveHCPLive
High cardiovascular riskEntry rules were age 70 and older, two or more chronic conditions, no known ASCVD and a year on a statinNo risk-group results appear in the HCPLive, Healio or ACC coverageHCPLive, Healio, ACC
Two or more chronic conditionsYes. This was an entry requirementThe whole trial population; the protocol describes STREAM as a trial in multimorbid older adults without cardiovascular diseaseSTREAM protocol, HCPLive

Several points about STREAM are still open. The HCPLive, Healio and ACC coverage reports no separate result for people 75 and older and none for the nearly one in three participants with diabetes. Healio's figures for follow-up up to four years come without hazard ratios or a median follow-up time.

The trial was open-label, so participants and doctors knew who had stopped, a limitation HCPLive notes, and there was no placebo arm. The full NEJM paper was not available at the time of writing, and Medscape's coverage is behind a paywall.

Rodondi said in Healio's report that for an individual patient, "the 2-week difference [in event-free survival] might not be worth continuing to take a statin if they have other issues." Karen Alexander, a cardiologist quoted in the same report, said: "what STREAM should not be interpreted as is that we should go and stop medicines for primary prevention."

Dennis Mwangi
Written by

Dennis Mwangi

Dennis Mwangi covers nutrition and fitness news. He reads the new studies behind each story and reports what they actually found.

View profile

No comments yet. Be the first to comment!

Leave a Comment

◆ Newsletter

Ideas worth your inbox.

The best new stories, startups and AI tools every week. No noise, unsubscribe anytime.